Sat, Aug 2, 2014, 5:28 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

  • terry_insm terry_insm Feb 21, 2013 12:25 PM Flag

    Investors in biotech are,and should be skeptical of hypotheticals

    Additions approvals markets are years and trials away and we haven't even gotten the dog results.There are social financial and regulatory roadblocks ahead so we start with basic premises,not Billions nonsense
    At this point I am as the CEO said "cautiously optomistic".
    Bios do best when they understate and overacheive.
    Until we get solid news,I will trade Insmed as a penny stock.Right now I have been very active trading as the markets are voluminous
    Gold looks like a good bounce play ;-)
    Good Luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • terry_insm•Feb 21, 2013 12:25 PMFlag

      Investors in biotech are,and should be skeptical of hypotheticals
      Additions approvals markets are years and trials away and we haven't even gotten the dog results.There are social financial and regulatory roadblocks ahead so we start with basic premises,not Billions nonsense
      At this point I am as the CEO said "cautiously optomistic".
      Bios do best when they understate and overacheive.
      Until we get solid news,I will trade Insmed as a penny stock.Right now I have been very active trading as the markets are voluminous
      Gold looks like a good bounce play ;-)
      Good Luck

      • 2 Replies to insm_truth_teller
      • terry_insm•Feb 21, 2013 12:25 PMFlag

        Investors in biotech are,and should be skeptical of hypotheticals
        Additions approvals markets are years and trials away and we haven't even gotten the dog results.There are social financial and regulatory roadblocks ahead so we start with basic premises,not Billions nonsense
        At this point I am as the CEO said "cautiously optomistic".
        Bios do best when they understate and overacheive.
        Until we get solid news,I will trade Insmed as a penny stock.Right now I have been very active trading as the markets are voluminous

      • by terry_insm•
        Investors in biotech are,and should be skeptical of hypotheticals
        Additions approvals markets are years and trials away and we haven't even gotten the dog results.There are social financial and regulatory roadblocks ahead so we start with basic premises,not Billions nonsense
        At this point I am as the CEO said "cautiously optomistic".
        Bios do best when they understate and overacheive.
        Until we get solid news,I will trade Insmed as a penny stock.Right now I have been very active trading as the markets are voluminous
        Gold looks like a good bounce play ;-)
        Good Luck

    • Truer words never spoken.

      • 1 Reply to kennethtdc
      • by terry_insm•Feb 21, 2013 12:25 PMFlag
        .

        Additions approvals markets are years and trials away and we haven't even gotten the dog results.There are social financial and regulatory roadblocks ahead so we start with basic premises,not Billions nonsense
        At this point I am as the CEO said "cautiously optomistic".
        Bios do best when they understate and overacheive.

    • by terry_insm•Feb 21, 2013 12:25 PMFlag
      .

      Additions approvals markets are years and trials away and we haven't even gotten the dog results.There are social financial and regulatory roadblocks ahead so we start with basic premises,not Billions nonsense
      At this point I am as the CEO said "cautiously optomistic".
      Bios do best when they understate and overacheive.
      Until we get solid news,I will trade Insmed as a penny stock.Right now I have been very active trading as the markets are voluminous
      Gold looks like a good bounce play ;-)
      Good Luck

 
INSM
17.25+0.16(+0.94%)Aug 1 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.